Bio-Thera Kicks Off Phase III Trial For Stelara Rival
Chinese Biosimilars Developer Begins Study For BAT2206 Ustekinumab Candidate
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.
